Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development
Ablynx NV
Alligator Bioscience AB
Apogenix AG
Avacta Life Sciences Ltd
Bristol-Myers Squibb Co
Checkpoint Therapeutics Inc
GigaGen Inc
Incyte Corp
Leap Therapeutics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles
ATOR-1144 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GITR for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWN-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-1876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1248 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Agonize GITR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Agonize GITR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Agonize GITR for Hematological Tumor and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Agonize GITR for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Product Development Milestones
Featured News & Press Releases
Dec 14, 2018: Leap therapeutics presents data on its oncology drug candidate TRX518 at ESMO Immuno-Oncology Congress 2018
Jan 16, 2018: Leap Therapeutics Announces First Patient Dosed with TRX518 Combition Therapy in Advanced Solid Tumors Trial
Nov 13, 2017: Leap Therapeutics Provides Update on its Antineoplastic Drug Candidate TRX-518
Apr 03, 2017: Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 at the 2017 AACR Annual Meeting
Mar 07, 2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting
Mar 01, 2017: Leap Therapeutics to Present Clinical Data on TRX518 at 2017 AACR Annual Meeting
Nov 12, 2016: Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist
Jun 22, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
Jan 21, 2016: Agenus Announces Clearance of Investigatiol New Drug Application by the FDA for anti-GITR Antibody
Apr 05, 2011: Tolerx Presents Preclinical Data On New Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Feb 09, 2011: Tolerx Presents Preclinical Data On TRX518
Dec 14, 2010: Tolerx Initiates Phase I Clinical Trial Of TRX518 For Treatment Of Cancer
Dec 01, 2010: Tolerx And Cancer Research Institute Enter Collaboration To Accelerate Development Of TRX518
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Ablynx NV, H1 2019
Pipeline by Alligator Bioscience AB, H1 2019
Pipeline by Apogenix AG, H1 2019
Pipeline by Avacta Life Sciences Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Checkpoint Therapeutics Inc, H1 2019
Pipeline by GigaGen Inc, H1 2019
Pipeline by Incyte Corp, H1 2019
Pipeline by Leap Therapeutics Inc, H1 2019
Pipeline by Merck & Co Inc, H1 2019
Pipeline by Novartis AG, H1 2019
Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019